Source: Dr. Robert Driscoll 10/28/2024

Wedbush analysts Dr. Robert Driscoll, Dr. Ritika Das, and Sam Ravina, in a research report published on October 28, 2024, maintained their Outperform rating on Monte Rosa Therapeutics Inc. (GLUE:NASDAQ) while raising their price target to US$15.00 from US$11.00. The report follows Monte Rosa's announcement of a collaborative agreement with Novartis for the development of MRT-6160, its VAV1-degrader program.

The analysts highlighted the significant financial terms of the agreement, stating, "GLUE will receive an upfront payment of US$150M as well as total milestone payments of up to US$2.1B that will include US$1.5B in potential development and regulatory milestones that begin upon Ph 2 studies."

Regarding the partnership structure, the analysts noted, "Upon start of Ph 3 studies, 30% US P&L would be shared with Ph 3 development co-fund and ex-US tiered royalties. Importantly, NVS will cover the complete costs of Ph 2 studies and will obtain worldwide rights to develop, commercialize and manufacture MRT-6160 as well as other VAV MGDs."

The analysts viewed this collaboration positively, stating, "We view this favorable collaboration agreement as an additional robust validation of GLUE's QuEEN MGD platform (noting Novartis' significant efforts in the degrader space), as well as an acknowledgment of the significant potential opportunities around targeting VAV1 with a first in class degrader."

They also emphasized the strategic benefits, noting, "Furthermore, we note the likely accelerated timelines for the MRT-6160 development program overall, and significant extension of GLUE's operational cash runway, which we expect to allow advancement of its deep pipeline."

The report highlighted the ongoing Phase 1 SAD/MAD healthy subject study for MRT-6160 in autoimmune diseases, with initial data expected in 1Q:25.

Wedbush's valuation methodology is based on sales multiples. The analysts explained, "Our PT is derived from applying a 6x multiple to estimated US sales and a 15x multiple to EU royalties of MRT-2359 in 2031, discounted by 30% annually."

The analysts also outlined several risk factors, including potential clinical and regulatory failure of MRT-2359, challenges in achieving sales estimates, and possible commercial competition from current and future therapies.

In conclusion, Wedbush's increased price target to US$15 reflects growing confidence in Monte Rosa Therapeutics following the Novartis collaboration agreement. The share price at the time of the report of US$8.05 represents a potential return of approximately 86% to the analysts' target price, highlighting the significant upside potential as the company advances its development programs with its new partner.

Sign up for our FREE newsletter at: www.streetwisereports.com/get-news

Important Disclosures:

1. This article does not constitute investment advice and is not a solicitation for any investment. Streetwise Reports does not render general or specific investment advice and the information on Streetwise Reports should not be considered a recommendation to buy or sell any security. Each reader is encouraged to consult with his or her personal financial adviser and perform their own comprehensive investment research. By opening this page, each reader accepts and agrees to Streetwise Reports' terms of use and full legal disclaimer. Streetwise Reports does not endorse or recommend the business, products, services or securities of any company.
2. This article does not constitute medical advice. Officers, employees and contributors to Streetwise Reports are not licensed medical professionals. Readers should always contact their healthcare professionals for medical advice.

For additional disclosures, please click here.

Disclosures for Wedbush, Monte Rosa Therapeutics Inc., October 28, 2024

Analyst Certification We, Robert Driscoll, Ritika Das and Sam Ravina, certify that the views expressed in this report accurately reflect our personal opinions and that we have not and will not, directly or indirectly, receive compensation or other payments in connection with our specific recommendations or views contained in this report.

The Distribution of Ratings is required by FINRA rules; however, WS' stock ratings of Outperform, Neutral, and Underperform most closely conform to Buy, Hold, and Sell, respectively. Please note, however, the definitions are not the same as WS' stock ratings are on a relative basis. The analysts responsible for preparing research reports do not receive compensation based on specific investment banking activity. The analysts receive compensation that is based upon various factors including WS' total revenues, a portion of which are generated by WS' investment banking activities. Company Specific Disclosures This information is subject to change at any time. 2. WS managed a public offering of securities for Monte Rosa Therapeutics within the last 12 months. 4. WS has received compensation for investment banking services from Monte Rosa Therapeutics within the last 12 months. 5. WS provided Monte Rosa Therapeutics with investment banking services within the last 12 months.

Wedbush disclosure price charts are updated within the first fifteen days of each new calendar quarter per FINRA regulations. Price charts for companies initiated upon in the current quarter, and rating and target price changes occurring in the current quarter, will not be displayed until the following quarter. Additional information on recommended securities is available on request. Disclosure information regarding historical ratings and price targets is available: Research Disclosures *WS changed its rating system from (Strong Buy/ Buy/ Hold/ Sell) to (Outperform/ Neutral/ Underperform) on July 14, 2009. Applicable disclosure information is also available upon request by contacting the Research Department at (212) 833-1375, by email to leslie.lippai@wedbush.com. You may also submit a written request to the following: Wedbush Securities, Attn: Research Department, 142 W 57th Street, New York, NY 10019.

OTHER DISCLOSURES The information herein is based on sources that we consider reliable, but its accuracy is not guaranteed. The information contained herein is not a representation by this corporation, nor is any recommendation made herein based on any privileged information. This information is not intended to be nor should it be relied upon as a complete record or analysis: neither is it an offer nor a solicitation of an offer to sell or buy any security mentioned herein. This firm, Wedbush Securities, its officers, employees, and members of their families, or any one or more of them, and its discretionary and advisory accounts, may have a position in any security discussed herein or in related securities and may make, from time to time, purchases or sales thereof in the open market or otherwise. The information and expressions of opinion contained herein are subject to change without further notice. The herein mentioned securities may be sold to or bought from customers on a principal basis by this firm. Additional information with respect to the information contained herein may be obtained upon request. Wedbush Securities does and seeks to do business with companies covered in its research reports. Thus, investors should be aware that the firm may have a conflict of interest that could affect the objectivity of this report. Investors should consider this report as only a single factor in making their investment decision. Please see pages 3–7 of this report for analyst certification and important disclosure information. Retail Investors The information provided is for general informational purposes only and should not be considered an individual recommendation or personalized investment advice. The companies/investments mentioned may not be suitable for everyone. Each investor needs to review their own respective situation(s) before making any investment decisions. All expressions of opinion are subject to change without notice due to shifting market(s), economic or political conditions. Investment involves risks including the risk of principal. Past performance is no guarantee of future results and the opinions presented cannot be viewed as an indicator of future performance.

( Companies Mentioned: GLUE:NASDAQ, )

Source: Streetwise Reports 11/08/2024

Vertex Pharmaceuticals Inc. (VRTX:NASDAQ) has reported a robust financial performance for the third quarter of 2024. The report has demonstrated the company's continued revenue growth and the strengthening of its innovative pipeline. For Q3 2024, Vertex's product revenue reached US$2.77 billion, a 12% increase from the previous year. This was primarily driven by strong demand for its TRIKAFTA®/KAFTRIO® therapies. Based on this momentum, Vertex raised its full-year product revenue guidance to a range of US$10.8 billion to US$10.9 billion, citing a solid trajectory in its cystic fibrosis (CF) portfolio and expected future launches.

In Q3, the company made notable advancements in its pipeline. Three programs have begun moving into Phase 3 clinical development: suzetrigine in diabetic peripheral neuropathy (DPN), povetacicept in IgA nephropathy (IgAN), and VX-880 in type 1 diabetes (T1D). Vertex is also preparing for the launch of two potential treatments in early 2025, with PDUFA dates set for January 2 for the vanzacaftor triple therapy for CF and January 30 for suzetrigine, the latter being a pain medication in a new therapeutic class aimed at reducing reliance on opioids.

GAAP and Non-GAAP net income both reached US$1.0 billion, largely driven by increased product revenue, which offset rising R&D and SG&A expense. This was s due to investments in global commercialization and late-stage clinical development. For Q3, Vertex's combined R&D and SG&A expenses were US$1.2 billion and US$1.1 billion, respectively, an increase from last year attributed to new global program advancements and upcoming launch support.

Vertex's cash position remained strong, with US$11.2 billion in cash, cash equivalents, and marketable securities as of September 30. The decline from US$13.7 billion at the end of 2023 primarily reflects the acquisition of Alpine Immune Sciences and share repurchases under the company's buyback program.

A Look At Biotechnology and Pharma

The U.S. Pharmaceuticals Report for 2024 by Nova One Advisor detailed the size and growth trajectory of the U.S. pharmaceutical market. Valued at US$602.19 billion in 2023, the sector is projected to exceed US$1 trillion by 2033. The report pointed to a "high healthcare expenditure provided by government bodies" as a primary growth driver, further bolstered by the aging population's demand for advanced treatments.

In an October 24 article, The Investing News Network reported on a dynamic landscape within the biotechnology sector. The report highlighted advancements in AI-powered drug discovery. Despite a cautious investment climate, interest remained strong in AI's potential to reshape healthcare, with venture capital investment reaching US$6.59 billion. At the HealthTech Ignite conference, Susie Roberts from Relay Therapeutics expressed confidence, noting, "We will definitely see AI design drugs in the next 10 years."

On November 4, Yahoo! Finance shared insights from MIT professors Andrew Lo and Dennis Whyte. They emphasized that biotechnology's rapid advancement over the past five decades offers valuable lessons for future innovation. In their research paper, Lo and Whyte proposed initiatives to accelerate biotechnology's growth, underscoring the importance of "reducing risk and uncertainty" to foster a robust investment ecosystem that supports groundbreaking discoveries.

Catalysts Driving Vertex Pharma

According to Vertex's November 2024 investor presentation, the company sees multiple growth catalysts over the next few years. Vertex aims to meet its goal of achieving "five launches in five years," focusing on expanding the treatable patient base in CF with vanzacaftor triple, addressing critical needs in sickle cell disease (SCD) and beta thalassemia (TDT) with CASGEVY, and launching suzetrigine for acute pain management.

Additionally, Vertex expects its expansive R&D pipeline to support long-term growth. This includes pivotal clinical trials for VX-880 in T1D, povetacicept in IgAN, and NaV1.8 pain inhibitors like suzetrigine, indicating a commitment to treating a range of chronic and life-threatening conditions with limited therapeutic options.

By driving advancements in CF therapies, diversifying its portfolio with novel pain treatments, and pursuing accelerated approvals for renal and blood-related disorders, Vertex is strategically positioning itself to sustain growth and achieve several near-term milestones.

What Are Experts Saying About Vertex?

In a November 5, 2024, H.C. Wainwright & Co. update, the analysts highlighted promising data from Vertex's recent Phase 2 trial for suzetrigine, which showed encouraging reductions in pain intensity. [OWNERSHIP_CHART-4085]

The analysts noted that suzetrigine's peripheral nervous system-specific mechanism could potentially address "a significant, unmet medical need worldwide" in non-opioid pain management. They set a price target of US$600.00, projecting Vertex's continued growth from its strong cystic fibrosis franchise and pipeline expansion.

From the November 7 Kingswood Capital Partners report, analysts noted Vertex Pharmaceuticals' "sustained execution" in advancing product development programs and achieving robust operating margins, enabling "continued, significant investments" in both its pipeline and commercial capabilities. The firm maintained a "Buy" rating with a 12-month target price of US$550.00, attributing this outlook to Vertex's deep cash resources and historical successes in clinical trials.

Ownership and Share Structure

According to Refinitiv, 95.44% of Vertex Pharmaceuticals is held by Institutions. The top among them are Capital World Investors at 10.37%, The Vanguard Group at 8.88%, BlackRock Institutional Trust with 5.49%, State Street Global Advisors (US) with 4.55%, and Fidelity Management and Research with 4.11%. Strategic Investors hold .12%. The rest is retail.

The company's market cap is US$129,395.59 million with 257.07 million free float shares. The 52 week range is US$341.90–$510.64.

Sign up for our FREE newsletter at: www.streetwisereports.com/get-news

Important Disclosures:

1) James Guttman wrote this article for Streetwise Reports LLC and provides services to Streetwise Reports as an employee.

2) This article does not constitute investment advice and is not a solicitation for any investment. Streetwise Reports does not render general or specific investment advice and the information on Streetwise Reports should not be considered a recommendation to buy or sell any security. Each reader is encouraged to consult with his or her personal financial adviser and perform their own comprehensive investment research. By opening this page, each reader accepts and agrees to Streetwise Reports' terms of use and full legal disclaimer. Streetwise Reports does not endorse or recommend the business, products, services or securities of any company.

For additional disclosures, please click here.

( Companies Mentioned: VRTX:NASDAQ, )

On-Demand Webinar > >> Watch Now! SPONSORED BY: HP Imaging and Printing GroupBy 2013, there will be 10 million telecommuters in the U.S., according to research firm IDC¹. Watch this FREE...

Dryden Gold Corp. (DRY:TSXV; DRYGF:OTCQB) has announced its participation in three significant mining investment conferences scheduled for November 2024. Read more about the company's plans to showcase major project updates and connect with global investors at these key events.

; Credit: /Courtesy of TED

Part 3 of TED Radio Hour episode: An SOS From The Ocean

In 1998, Alasdair Harris went to Madagascar to research coral reefs. He's worked there ever since. He explains the true meaning of conservation he learned from the island's Indigenous communities.

About Alasdair Harris

Alasdair Harris is a marine biologist and the founder of the organization Blue Ventures. His organization seeks to catalyze and sustain locally-led marine conservation in coastal communities around the world.

His work focuses on rebuilding tropical fisheries and working with coastal people to increase their sources of income.

Harris holds a PhD in tropical marine ecology, and an honorary doctorate of science from the University of Edinburgh.

This segment of TED Radio Hour was produced by Matthew Cloutier and edited by Sanaz Meshkinpour. You can follow us on Twitter @TEDRadioHour and email us at TEDRadio@npr.org.

This content is from Southern California Public Radio. View the original story at SCPR.org.

"The Commission made binding commitments offered by T-Mobile CZ, CETIN and O2 CZ that will keep the benefits of network sharing whilst removing technical and financial disincentives to unilateral deployments and limiting information exchange, all to the benefit of Czech mobile user," Commission Vice-President Margrethe Vestager said in a statement.

Panelists in a discussion on ‘Mobility Megatrends 2050’, highlighted that in the next decade, with electrification, autonomous driving, smart and connected infrastructure, modal diversity, and mobility that is integrated, resilient, shared, and sustainable – powered by disruptive business models, will transform and shape up of the automotive industry. The industry is racing towards a new world, driven by sustainability and changing consumer behaviour, encompassing electric vehicles, autonomous cars, mobility fleet sharing, and always connected.

“The technology services industry, at some level, is recession proof,” Premji said at the company’s 76th annual general meeting on Tuesday. “In good times, clients spend on new initiatives and business transformation and serving customers digitally. They focus on reducing costs when times are not so good,” he said addressing a question on inflation concerns.

Through a series of ambitious initiatives and strategic investments, India is actively working to overcome barriers and create a level playing field for technology adoption. From expanding connectivity infrastructure to investing in digital literacy programs, the nation is leaving no stone unturned in its pursuit of equitable access to technology.

Many business users have approached generative AI technology more cautiously because it can make up untrue facts and be tricked into saying unsettling things. Oracle's human resources software is used by big businesses for hiring new employees and providing performance evaluations, among other things. Oracle will put a button on many of the fields in the software that will automatically generate draft text for things like job listings or performance goals.

Microsoft-owned OpenAI has announced the general availability of its latest text-generating model GPT-4, through its API.

In the fall of 2009, as a part of the Catawba Aging Leadership Planning Project, Catawba County, along with aging service providers, volunteers and local municipalities developed a �Livable & Senior Friendly Community Survey�. This survey was widely distributed throughout Catawba County and targeted the County�s Senior Community, their caregivers and professionals in the aging field. The purpose of the survey was to obtain current and relevant information on the quality of life of seniors. Obtaining this information is important when looking toward the future of Catawba County.

Bryan Blanton, who has steadily risen in positions of responsibility from paramedic to Training Officer to Manager of Emergency Medical Services, will now permanently supervise all of Catawba County's Emergency Services.

Cynthia Eades, a long-time resident of Catawba County who is currently serving as Human Resources Director in Iredell County and has ten years of experience in local government human resources, has been named Catawba County�s new Human Resources Director. She will begin her new duties with Catawba County on July 1, 2010.

Cyndy Benson, who recently retired as Family and Children�s Services program manager in the Department of Social Services, has received the Kimberly F. Crews Memorial Award from the N.C. Professional Society on the Abuse of Children. This award is presented annually to honor a person who works directly with children suspected of having been abused.

Family Builders, the adoption service of Catawba County Social Services, can now help adult adoptees, birth parents and their close relatives find each other. Not all counties in North Carolina offer this service, which is called Confidential Intermediary Services. Until recently all adoption records were sealed under North Carolina state law. In 2008, a new law took effect that allowed the release of certain records to adult adoptees and birth parents, if both parties agreed.

A Catawba County Department of Social Services program that helped teenagers enrolled in a poverty reduction and teen pregnancy program better understand the myths of government support programs has been named a winner of a 2011 National Association of Counties (NACo) Achievement Award.

Senior Nutrition Services is now housed at 507 Boundary Street in Conover. Senior Nutrition Services includes Home Delivered Meals (Meals on Wheels), Seniors Morning Out, Nutritional Supplements (Ensure and Boost), Frozen Meals, and In Home Aide Services.

Anyone accessing My Catawba County will be able to choose from a selection of informational links and County applications. The application was developed for mobile devices with a web browser such as iPad, iPhone, Android phones and tablets.

Area youth participating in the NC Cooperative Extension�s 4-H program helped children at Catawba County Public Health plant vegetable seeds. The activity was one of a series of visits by local North Carolina Cooperative Extension staff and volunteers to Public Health�s Women, Infants and Children (WIC) clinic designed to encourage WIC families to grow and eat fresh vegetables.

You may now access the Catawba County Library System website from your smartphone, thanks to a recent upgrade to the library�s home page. LS2Mobile is accessible with an iPod Touch or iPhone.

�Catawba Communities,� a monthly show which will feature information about programs and services provided by local governments, school systems and associated agencies across Catawba County, will premiere on Charter Communications� Government Channel (Channel 3) on Tuesday, August 23, 2011, at 8:00 p.m.

What if the August 23 earth tremors had been closer or stronger? Would you know what to do? Here are some tips from Catawba County Emergency Services.

Vaccines will be administered on a first-come, first-serve basis, from 11:00 a.m. to 3:00 p.m., or until the supply is depleted on September 21, World Rabies Day, thanks to 250 vaccines provided by the World Rabies Organization and Pfizer Animal Health.

The award was presented for the agency's Children and Aging Strategic Planning Projects in the category �Profiles in Community Collaboration�. The entry described the Children�s Agenda Planning Committee and the Aging Leadership Planning Project. In both cases, Social Services took the lead in collaborating with area agencies to develop reports about the needs of children and older adults.

The United States Environmental Planning Agency (USEPA) has announced that Catawba County will be classified as �attainment� from its current �nonattainment� designation for Particulate Matter 2.5 (PM 2.5) on December 19, 2011. PM 2.5 (fine particle pollution) refers to tiny particles of droplets in the air that are two and one half microns or less in width. Two and one half microns is about thirty times smaller than the width of a human hair.

Enhancements include an auto-fill feature, the ability to search on a business or landmark name, and links to both Google and Bing maps.

The agreement would substantially increase the number of items collected for recycling across Catawba County, with further expansion of items collected as needed over time; begin �single stream� collection of recyclable commodities so recycled materials would no longer be required to be separated at curbside; increase Republic Services� investment in Catawba County by $13 million; and protect more than 150 local jobs.

Catawba County will mail data verification, income and expense request, to property owners as 2015 revluation process continues on May 17, 2013. Owners are requested to verify the information found on the data verification sheet, provide pertinent additional information and make any necessary corrections, and return the form to the revaluation office. http://www.catawbacountync.gov/events/revalmailer13.asp

A new County Solid Waste Franchise with Republic Services (formerly known as GDS), effective July 1, is bringing expanded recycling, new fee schedule, services.

Adult Services Social Worker Chandra Henson with Catawba County Social Services has been honored by the North Carolina Adult Foster Care Association.

Catawba County Library Library system announces staff changes. April Green named Youth Services Librarian; Siobhan Loendorf new manager of Sherrills Ford branch.

Social Services program honored as one of only 15 programs in U.S. making critical difference in lives of youth in foster care.

Lisa Przekop, director of admissions at University of California, Santa Barbara, says that many high schoolers this year wrote their application essays about depression and anxiety during the pandemic.; Credit: Patricia Marroquin/Moment Editorial/Getty Images

College-bound high schoolers are making their final deliberations ahead of May 1, the national deadline to pick a school. That day will mark the end of a hectic admissions season drastically shaped by the COVID-19 pandemic.

Many colleges dropped standardized testing requirements, and because some high schools gave pass/fail grades and canceled extracurriculars and sports, admissions counselors had to change how they read and evaluate applications.

"[It was] definitely the craziest of all my 36 years, without a doubt," says Lisa Przekop, director of admissions at the University of California, Santa Barbara.

The UC school system received the most applications in the United States.

Like many others, Przekop says all of her staff has been working remotely throughout the pandemic. But if pivoting to working from home wasn't a challenge enough, Przekop says the school saw an increase in applications of 16%.

"On top of all that, we had to devise a way of doing our admissions selection process without the use of SAT or ACT scores," she says. "So any one of those things would have been a major change, but to have all of them at the same time was beyond anything really that I could've imagined."

Przekop spoke with All Things Considered about how what counselors looked for in applications this year changed, what topics they saw in admissions essays and how the process might have actually improved in spite of the pandemic.

This interview has been edited for length and clarity.

Interview Highlights

Has it all added up to more time spent on every individual application?

Quick answer, yes. Things are much more nuanced now. And although a student may have, for instance, planned to do certain activities, well many of those activities were canceled. The other big difference was students were a lot more depressed this year, obviously. Everybody's more anxious, including students. They're applying for college which is stressful in and of itself. And so what we found is a lot of students used their essays to talk about depression, anxiety, things like this. To read essay after essay after essay about depression, anxiety, stress — is taxing. And so we really had to encourage staff to take more breaks as they were reviewing. So it definitely slowed the whole process down at a time when we had more applications to review.

Can you give any insight into what you are basing your decisions on this year?

Absolutely. Maybe in the past I would've focused on that GPA right away. Now when I'm looking at that academic picture, I have to look at the fact that did the student challenge themselves as much as they could have? Were the courses even available? Do I see any trends in their academic performance? If their spring term of last year, their junior year, was all pass/no pass, can I safely assume that they did well in those courses? And that's where you really had to rely on what the students shared in their essays to try to piece that together.

Are you noticing greater diversity in the students applying to UC?

In terms of ethnic diversity, yes, we are seeing that. In terms of diversity of experience — for instance, first generation students and students with lots of different socioeconomic backgrounds — we're definitely seeing that. I'm seeing students who are very committed to the environment more so than i've seen before. I'm seeing students who are more politically aware and active than I've seen before. So I'm definitely seeing a pattern of behaviors that look a little bit different than students in the past.

This content is from Southern California Public Radio. View the original story at SCPR.org.

Cancer-causing chemicals that occur naturally in foods are far more numerous in the human diet than synthetic carcinogens, yet both types are consumed at levels so low that they currently appear to pose little threat to human health, a committee of the National Research Council said in a report released today.

Recent strides in biotechnology offer the promise of new and innovative applications -- from edible vaccines to protein-based electronics components.

Eleven questions that should shape the next decade of geographical sciences research were identified today in a new report by the National Research Council.

Most Americans and Canadians up to age 70 need no more than 600 international units (IUs) of vitamin D per day to maintain health, and those 71 and older may need as much as 800 IUs, says a new report from the Institute of Medicine.

A new report from the Institute of Medicine (IOM) recommends that eight preventive health services for women be added to the services that health plans will cover at no cost to patients under the Patient Protection and Affordable Care Act of 2010 (ACA).

Educational and business leaders want todays students both to master school subjects and to excel in areas such as problem solving, critical thinking, and communication

President Barack Obama reiterated his strong support for science and technology today in a speech to members of the National Academy of Sciences at its 150th annual meeting.

The U.S. National Academy of Sciences and the Royal Society, the national science academy of the U.K., released a joint publication today in Washington, D.C., that explains the clear evidence that humans are causing the climate to change, and that addresses a variety of other key questions commonly asked about climate change science.

A new report from the National Research Council recommends best practices that law enforcement agencies and courts should follow to improve the likelihood that eyewitness identifications used in criminal cases will be accurate.

The National Academy of Sciences and the National Academy of Medicine are launching a major initiative to guide decision making about controversial new research involving human gene editing.

The best indicator of whether a disabled adult who receives Social Security benefits is capable of managing his or her benefits is evidence of real-world performance of meeting his or her own basic needs, rather than an office-based assessment of financial competence, says a new report from the National Academies of Sciences, Engineering, and Medicine.

A new report from the National Academies of Sciences, Engineering, and Medicine identifies six promising practices to improve health care for individuals with social risk factors for poor health care outcomes, such as people who are in a low socio-economic position, reside in disadvantaged neighborhoods, identify as a racial or ethnic minority, or possess limited health literacy.

Bullying is a serious public health problem, with significant short- and long-term psychological consequences for both the targets and perpetrators of such behavior, and requires a commitment to developing preventive and interventional policies and practices that could make a tangible difference in the lives of many children, says a new report from the National Academies of Sciences, Engineering, and Medicine.

An extensive study by the National Academies of Sciences, Engineering, and Medicine has found that new technologies in genetic engineering and conventional breeding are blurring the once clear distinctions between these two crop-improvement approaches.

Hearing loss is a significant public health concern, and efforts should be made to provide adults with easier access to and more affordable options for hearing health care, especially for those in underserved and vulnerable populations, says a new report from the National Academies of Sciences, Engineering, and Medicine.

A new report from the National Academies of Sciences, Engineering, and Medicine provides a comprehensive assessment of economic and demographic trends of U.S. immigration over the past 20 years, its impact on the labor market and wages of native-born workers, and its fiscal impact at the national, state, and local levels.